Cancer combo trial pulled before starting
NCT ID NCT03402880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test two drugs, pembrolizumab and epacadostat, together in people with advanced small cell lung cancer that had already been treated with chemotherapy. The goal was to see if the combination could shrink tumors or slow the cancer. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope South Pasadena
South Pasadena, California, 91030, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung cancer trial tests two new combo therapies against tough disease
- Could a PARP inhibitor boost chemo for tough lung cancer?
- New radiation technique aims to protect memory in lung cancer patients
- Immunotherapy-Radiation combo shows promise in tough lung cancer
- Old arthritis drug paired with immune suppressant shows promise against tough lung cancers